Drug intelligence / Profile preview

KB-20V

Development stage: Unknown
Lead developer: KBio
Modality: Vaccines & Immunotherapeutics

Overview

KB-20V is a prophylactic vaccine developed by KBio Inc. for the prevention of infectious diseases, specifically targeting respiratory diseases such as COVID-19. The drug is currently in Phase 1 clinical development. Its mechanism of action and specific molecular targets have not been disclosed publicly, but as a prophylactic vaccine for COVID-19, it is designed to induce an immune response against the coronavirus[1].

Brand names: KB-20VKB20VKB 20V
Other names: KB-20VKB20VKB 20V

Beyond the preview

Go deeper on KB-20V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB-20V.

Explore the full profile